HeartBeam, Inc. Quarterly Report on Form 10-Q for the Quarter Ended March 31, 2024

Press release · 05/10 17:24
HeartBeam, Inc. Quarterly Report on Form 10-Q for the Quarter Ended March 31, 2024

HeartBeam, Inc. Quarterly Report on Form 10-Q for the Quarter Ended March 31, 2024

HeartBeam, Inc. has filed its quarterly report on Form 10-Q for the period ended March 31, 2024. The company is a smaller reporting company and an emerging growth company. It has not elected to use the extended transition period for complying with new or revised financial accounting standards. The company’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and is traded on the NASDAQ under the symbols BEAT and BEATW. The company’s financial report contains forward-looking statements regarding its future plans, objectives, expectations, and intentions.

Financial Performance Overview

HeartBeam is a medical technology company developing innovative cardiac monitoring solutions. In 2024, the company made progress on key milestones but also reported increased losses driven by higher research and development costs.

As HeartBeam’s products are still under development and pending regulatory clearance, the company reported no revenue in Q1 2024 or 2023. Net losses increased from $4.1 million in Q1 2023 to $4.6 million in Q1 2024, an 11% increase, primarily driven by higher R&D expenses.

HeartBeam expects to begin commercialization by end of 2024 if FDA clearance is obtained as planned. As a development stage company focused on innovative products, losses are expected to continue in the near term. Profitability likely depends on successful commercial ramp post-launch.

Cash Resources

HeartBeam held $12.6 million in cash at March 31, 2024. Based on current burn rates, management indicates there is doubt about having sufficient capital to fund operations for the next 12 months. Additional financing will be required until the company can achieve positive cash flow.

Key Developments

Major Q1 2024 developments included:

  • Enrolled first patient in pivotal VALID-ECG study for FDA submission
  • Presented initial AI algorithm data at medical conferences
  • Progressed on 510(k) submission for AIMIGo device clearance

Additionally, in early Q2 2024, HeartBeam established an at-the-market (ATM) equity facility for up to $17 million. While helpful for incremental capital needs, larger financings may still be required for commercialization.


If HeartBeam achieves FDA clearance as planned in late 2024, it will be positioned to begin commercializing its innovative cardiac monitoring solutions. Key factors shaping the outlook include:

  • Execution on regulatory timelines
  • Success of VALID-ECG pivotal study
  • Sufficient funding to drive commercialization
  • Market adoption and reimbursement

With its proprietary VECG platform and AI capabilities, HeartBeam aims to transform cardiac care. But the company must still meet critical milestones, secure additional capital, and demonstrate real-world value for providers and payors.

Analysis of Financial Statements

Operating Expenses

HeartBeam’s operating expenses rose 15% year-over-year to $4.8 million in Q1 2024.

  • R&D costs increased 44% to $2.4 million, reflecting investments in HeartBeam’s product pipeline like the VALID-ECG study as well as growing technical staff. This underscores the company’s focus on innovation.

  • G&A costs declined 5% to $2.4 million as lower commercial and investor relations expenses offset increased stock compensation costs.

Cash Flow and Balance Sheet

HeartBeam reported no financing activities in Q1 2024. Key changes in the company’s financial position included:

  • Cash balance decreased by $3.3 million to $12.6 million at March 31, 2024, down from $15.9 million at December 31, 2023, reflecting operating losses. This raises concerns about near-term funding needs.

  • Working capital declined to $12.1 million from $15.4 million over the same period, largely tracking the drop in cash.

  • With no debt, the balance sheet remains straightforward. But the ample cash balance HeartBeam held after its 2021 IPO has now dwindled, putting pressure on the company to raise additional capital within the next 12 months.

Key Metrics

With no revenue, HeartBeam’s financial metrics remain limited. But analyzing cash burn provides insights:

  • Q1 2024 operating cash burn of $3.3 million suggests an annualized cash burn rate approaching $13 million.

  • At that rate, the latest $12.6 million cash balance only covers operations for about 12 more months. This highlights the urgency of securing additional funding.

Historical Performance

As a younger clinical-stage company, HeartBeam has a limited financial history:

Key Metric 2021 2022
Net Loss $11.9 million $19.8 million
Cash Balance $29.3 million $16.1 million

With cash consumption accelerating, 2023 losses could approach $25 million. The recent ATM facility provides HeartBeam with some capital flexibility to bridge to future financings but likely not enough to fully fund operations if commercialization is achieved.